United States Code · Part
Part E — General Provisions Relating To Drugs And Devices
21 U.S.C. pt. ptE
- § 360bbb Expanded Access To Unapproved Therapies And Diagnostics
- § 360bbb–0 Expanded Access Policy Required For Investigational Drugs
- § 360bbb–0a Investigational Drugs For Use By Eligible Patients
- § 360bbb–1 Dispute Resolution
- § 360bbb–2 Classification Of Products
- § 360bbb–3 Authorization For Medical Products For Use In Emergencies
- § 360bbb–3a Emergency Use Of Medical Products
- § 360bbb–3b Products Held For Emergency Use
- § 360bbb–3c Expedited Development And Review Of Medical Products For Emergency Uses
- § 360bbb–4 Countermeasure Development, Review, And Technical Assistance
- § 360bbb–4a Priority Review To Encourage Treatments For Agents That Present National Security Threats
- § 360bbb–4b Medical Countermeasure Master Files
- § 360bbb–5 Critical Path Public-private Partnerships
- § 360bbb–5a Emerging Technology Program
- § 360bbb–6 Risk Communication
- § 360bbb–7 Notification
- § 360bbb–8 Consultation With External Experts On Rare Diseases, Targeted Therapies, And Genetic Targeting Of Treatments
- § 360bbb–8a Optimizing Global Clinical Trials
- § 360bbb–8b Use Of Clinical Investigation Data From Outside The United States
- § 360bbb–8c Patient Participation In Medical Product Discussion
- § 360bbb–8d Notification, Nondistribution, And Recall Of Controlled Substances